Is Oculis Holding AG (OCS) a Buy, Sell, or Hold?
Oculis Holding AG
NASDAQ:OCS
$12.93 USD
-$0.22 (-1.67%)
- Volume
- 312.41K
- Average Volume
- 730.12K
- Market Capitalization
- $739.2M
- P/E Ratio
- -6.05
- Dividend Yield
- 0.00%
- Price Target
- $38.00
- Year High
- $34.48
- Year Low
- $10.52
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.18
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Riad Sherif |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | OCS |
| CUSIP | None |
| CIK | 0001953530 |
| Web | https://oculis.com |
| Phone | 41 58 810 0182 |
| Currency | USD |
| Employees | 60 |
| Country | CH |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.18 |
| Quick Ratio | 5.18 |
| Cash Ratio | 1.47 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 1186.27 |
| Cash Flow | -1.07 |
| Price / Cash Flow | -9.46 |
| Price / Book | 3.14 |
Price Target and Rating
| Average Stock Price Forecast | $38.00 |
| High Stock Price Forecast | $50.00 |
| Low Stock Price Forecast | $26.00 |
| Forecast Upside/Downside | -65.97% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.81 |
| Trailing P/E Ratio | -6.05 |
| PEG Ratio | -0.18 |
| P/E Growth | -0.18 |
| Net Income | $-94.51M |
| Net Margin | -18861.29% |
| Pretax Margin | -18919.18% |
| Return on Equity | -57.09% |
| Return on Assets | -39.08% |
Financials Score
| AltmanZ Score | 5.01 |
| Piotroski Score | 3.00 |
| Working Capital | 182.63M |
| Total Assets | 243.26M |
| Ebit | -94.55M |
| Market Cap | 610.69M |
| Total Liabilities | 47.2M |
Poll Results
About Oculis Holding AG (NASDAQ:OCS) Stock
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diab ... etic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
2026-07-08 16:05:00
ZUG, Switzerland, July 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
2026-07-02 04:00:00
ZUG, Switzerland, July 2, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis' management will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference.
2026-06-25 10:00:00
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-06-23 17:46:00
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG (“Oculis” or the “Company”) (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
2026-06-18 10:00:00
NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-06-17 09:44:00
LOS ANGELES, June 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding AG (“Oculis” or “the Company”) (NASDAQ: OCS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2026-06-16 17:03:00
NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG (“Oculis” or the “Company”) (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
2026-06-11 12:00:00
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or "the Company") (NASDAQ: OCS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Frequently Asked Questions
-
What is the current Oculis Holding AG (OCS) stock price?
-
Oculis Holding AG(NASDAQ:OCS) stock price is $12.93 in the last trading session. During the trading session, OCS stock reached the peak price of $34.475 while $10.52 was the lowest point it dropped to. The percentage change in OCS stock occurred in the recent session was --1.67% while the dollar amount for the price change in OCS stock was -$-0.22.
-
OCS's industry and sector of operation?
-
The NASDAQ listed OCS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of OCS?
-
Virginia R. Dean | Chief Human Resources Officer
Riad Sherif | Chief Executive Officer & Director
Sharon Klier | Chief Development Officer
Snehal Shah | President of Research & Development
Rebecca Weil | Chief Commercial Officer -
How many employees does OCS have?
-
Number of OCS employees currently stands at 60. OCS operates from Bahnhofstrasse 7, Zug, ZG 6300, CH.
-
Link for OCS official website?
-
Official Website of OCS is: https://oculis.com
-
How do I contact OCS?
-
OCS could be contacted at phone #41 58 810 0182 and can also be accessed through its website. OCS operates from Bahnhofstrasse 7, Zug, ZG 6300, CH.
-
How many shares of OCS are traded daily?
-
The average number of OCS shares traded daily for last 3 months was 730.12K.
-
What is the market cap of OCS currently?
-
The market value of OCS currently stands at $739.2M with its latest stock price at $12.93